JAMP BRIMONIDINE/TIMOLOL 0.2 %
BRIMONIDINE TARTRATE : 0.2 % TIMOLOL (TIMOLOL MALEATE) : 0.5 % · DIN 02531704 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP BRIMONIDINE/TIMOLOL?
JAMP BRIMONIDINE/TIMOLOL 0.2 % contains BRIMONIDINE TARTRATE : 0.2 % TIMOLOL (TIMOLOL MALEATE) : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 02531704, held by JAMP PHARMA CORPORATION, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 21-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP BRIMONIDINE/TIMOLOL used for?
JAMP Brimonidine / Timolol is indicated for the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of JAMP Brimonidine / Timolol is considered appropriate. It also aids in the reduction of long-term fluctuation in IOP, which, along with IOP reduction, is expected to slow the progression of visual field loss in glaucoma patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02531704 |
|---|---|
| Brand name | JAMP BRIMONIDINE/TIMOLOL |
| Generic / active ingredient | BRIMONIDINE TARTRATE : 0.2 % TIMOLOL (TIMOLOL MALEATE) : 0.5 % |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 0.2 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED51 TIMOLOL, COMBINATIONS |
| AHFS class | 52:40.08 ; 52:40.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Jul-2023 |
| Original market date | 2023-07-21 00:00:00 |
How is it stored and handled?
null
How is it supplied?
white LDPE sterilized dropper bottle containing 10 mL solution
What can be used instead?
Other Canadian products sharing ATC code S01ED51 TIMOLOL, COMBINATIONS. 21 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | DIN 02299615 |
| APO-TRAVOPROST-TIMOP PQ | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02415305 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02278251 |
| JAMP-LATANOPROST/TIMOLOL | 5 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02453770 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.